New hope for advanced cervical cancer: drug combo aims to extend survival
NCT ID NCT07392060
First seen Feb 06, 2026 · Last updated May 20, 2026 · Updated 9 times
Summary
This phase 3 study tests whether a combination of two drugs (WX390 and toripalimab) helps people with recurrent or metastatic cervical cancer live longer compared to standard treatments. The study enrolls 440 adults aged 18-75 whose cancer has worsened after at least one round of platinum-based chemotherapy. The main goal is to see if the combo improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.